Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Managed Care June 2004 Thomas Morrow	Laronidase Opens Door To Treat Other Rare Disorders The release of alpha-L-iduronidase also demonstrates the wave of future treatments for many other mucopolysaccharidosis (MPS) diseases.
Managed Care September 2004 Thomas Morrow	Orphan Drug Act Treatments Deserve Full Insurance Coverage An important federal law encourages development of drugs for populations so small that the market would otherwise ignore them. Should they not then be covered?
Nursing June 2010 Daniel A. Hussar	New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs.
The Motley Fool August 10, 2010 Ryan McBride	Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive.
Pharmaceutical Executive July 1, 2011 Dickmeyer & Rosenbeck	From Rut to Racetrack Can the pharmaceutical industry deliver on its objective to make cancer a curable, chronic condition?
Pharmaceutical Executive November 1, 2012 Sue Barrowcliffe	Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options.
Pharmaceutical Executive April 10, 2014 Ben Comer	Sickle Cell Disease In Three Acts Is there a happy ending in store for sickle cell patients?
Pharmaceutical Executive November 1, 2011 Elizabeth O. Coulton	Clinical Trial Issues Not Just Black and White The selection of clinical trial participants must meld with the changing demographics of America if industry is to improve medicines that work for patients.
Nursing June 2011 Daniel A. Hussar	New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis.
Nurse Practitioner February 2011 Jennifer M. Belavic	Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available.
American Family Physician June 1, 2006 Raghuveer Et Al.	Inborn Errors of Metabolism in Infancy and Early Childhood: An Update Primary care physicians often are the first to be contacted by state and reference laboratories when neonatal screening detects the possibility of an inborn error of metabolism. Physicians must take immediate steps to evaluate the infant and should be able to access a subspecialty center.
Nursing March 2012 Daniel A. Hussar	New Drugs 2012: part I In this article, you'll learn about 11 recently approved drugs.
The Motley Fool June 6, 2011 Brian Orelli	Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market.
Nurse Practitioner July 2011 Lori Mertz	Meningococcal Disease: Early Recognition is Vital to Patient Outcomes Education of healthcare professionals to improve identification and provide immediate treatment of patients with symptoms consistent with meningococcal disease will result in improved outcomes.
Nursing February 2010 Daniel A. Hussar	New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs.
American Journal of Nursing October 2009	Pharmacogenomics: Personalizing Drug Therapy Pharmacogenomics is a rapidly growing field of research into the ways in which genetic variation affects drug response.
Nurse Practitioner August 2009 Linda A. Howe	Pharmacogenomics and management of cardiovascular disease Prior to the completion of the Human Genome Project in 2003, individual responses to medications were usually termed idiosyncrasies. Ethnic differences were not usually seen as genetic variants, as is the case today.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
Nurse Practitioner February 2012 Jennifer M. Belavic	Annual drug update 2011 in review Many new medications were approved throughout 2011. This article will cover a variety of drugs that will be useful in nurse practitioner practice
Nurse Practitioner July 2010 Kristine A. Scordo	Treating antiretroviral-induced dyslipidemia in HIV-infected adults Studies indicate that HIV-infected patients (both males and females) may be at an increased risk for the development of cardiovascular disease
Nurse Practitioner August 2010 Virginia Sun	Update on Pancreatic Cancer Treatment Pancreatic cancer is the 10th leading type of all new cancer cases and the fourth leading type of cancer death that affects both men and women.
Chemistry World December 24, 2014 Phillip Broadwith	EU recommends Parkinson's drug for approval The first new drug in 10 years for Parkinson's disease has been recommended for approval by the European Committee for Medicinal Products for Human Use.
Pharmaceutical Executive December 1, 2011 Ben Comer	Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?
Nursing February 2009 Daniel A. Hussar	New Drugs 09: Part 1 Learn about 10 new drugs, including nebivolol HCl, the newest beta-adrenergic blocking agent for hypertension.
Fast Company December 2009 Elizabeth Svoboda	Biotechs Look Overseas to Launch a Stem-Cell Revolution According to one small biotech, the best way to launch a stem-cell revolution is to do it overseas.
The Motley Fool September 23, 2010 Brian Orelli	Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease.
The Motley Fool December 15, 2009 Brian Orelli	Forget the Higher Doses Elan has to drop the highest dose of an Alzheimer's drug. Again.
The Motley Fool June 23, 2009 Brian Orelli	Wonder Drug! Maybe? Get the facts before jumping on this one.
The Motley Fool August 20, 2011 Luke Timmerman	Seattle Genetics Wins FDA Approval of First Drug FDA gives a quick turnaround on the new treatment for lymphomas.
Pharmaceutical Executive November 1, 2014 Josh Baxt	2015 Pipeline Report: Burning Bright The science of drug discovery is back on script and the stars are cued up for a new generation of breakthrough therapies.
Chemistry World July 2010 Anna Lewcock	Medicine made to measure Healthcare tailored to suit the genetic makeup of the patient is finally coming to fruition.
The Motley Fool September 14, 2010 Luke Timmerman	Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug.
Chemistry World April 24, 2008 James Mitchell Crow	FDA takes tough line on biologic drug The US Food and Drug Administration has rejected an application from biotechnology firm Genzyme to make its already-approved, protein-based drug Myozyme in larger batches.
Pharmaceutical Executive April 1, 2012 Feam & Lagus	Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help.
Nursing July 2011 Susan Simmons	Recognizing and Managing Rheumatoid Arthritis Here's what rheumatoid arthritis is, how it's diagnosed and treated, and what you can do to help patients manage the disease.
Nurse Practitioner September 2011 Cheryl L. Gainer	Celiac Disease: Helping Patients Live Gluten-Free A review of the screening, diagnosis, and treatment of celiac disease.
Nursing January 2011 Carl A. Kirton	HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness.
The Motley Fool January 3, 2011 Brian Orelli	Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure.
American Family Physician December 1, 2005 Potter, Rindfleisch & Kraus	Management of Active Tuberculosis Although the overall incidence of tuberculosis has been declining in the United States, it remains an important public health concern. Patients who present with symptoms of active tuberculosis (e.g., cough, weight loss, or malaise with known exposure to the disease) should be evaluated.
Managed Care November 2006 Maureen Glabman	Genetic Testing: Major Opportunity, Major Problems Whether a person is likely to develop diabetes, cancer, schizophrenia, or stroke will be reasonably well predicted, and tests can also determine whether a patient will respond to a given therapy. That's the good part.
The Motley Fool March 3, 2009 Brian Orelli	A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals.
Pharmaceutical Executive June 1, 2014 Jill Wechsler	Compassionate Use Requests Complicate Drug Development Pharma, HCPs, and regulators walk tightrope in addressing early-access push while supporting biomedical R&D.
Nursing June 2011 Cahill & Armstrong	Caring for an adult with a malignant primary brain tumor Pprimary brain tumors are relatively uncommon, occurring in an estimated 63,000 patients in the united states each year.
Pharmaceutical Executive June 1, 2014 Jill Wechsler	What Price Innovation? Payers, drug plans seek clear assessment of drug value to rationalize high drug prices.
Pharmaceutical Executive December 1, 2013 Vansgaard et al.	Develop Drugs for People, Not Just Bodies A patient-centric approach to drug development delivers the benefits that actually create value
The Motley Fool November 14, 2011 Brian Orelli	Biotech Uncertainty = Big Upside Potential Aastrom's phase 2 and phase 3 trials don't match up.
Pharmaceutical Executive October 1, 2011	Patient Advocacy: The Last 30 Years The rise of advocacy groups has helped patients find their voice, but the power to change health profiles remains an elusive goal.
Chemistry World October 10, 2014 Rebecca Trager	US ramps up rare diseases research The US National Institutes of Health is spending $29 million to fund research consortia that will study more than 200 rare diseases.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA
American Family Physician September 1, 2004 Ostapchuk, Roberts & Haddy	Community-Acquired Pneumonia in Infants and Children When diagnosing community-acquired pneumonia, physicians should rely mainly on the patient's history and physical examination, supplemented by judicious use of chest radiographs and laboratory tests as needed.